Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 20/20 | 0.84 |
| ▸ | HRH1 | P35367 | 20/20 | 0.84 |
| ▸ | ADRA1B | P35368 | 20/20 | 0.84 |
| ▸ | KCNH2 | Q12809 | 17/20 | 0.84 |
| ▸ | HRH3 | Q9Y5N1 | 17/20 | 0.84 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | HRH2 | P25021 | 1/20 | 0.55 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2430003 | 0.95 | ADRA1A (0.81) | ADRA1AHRH1ADRA1BKCNH2HRH3 | |
| SCHEMBL14155532 | 0.89 | HRH1 (0.83) | ADRA1AHRH1ADRA1BKCNH2HRH3 | |
| SCHEMBL2990460 | 0.89 | HRH1 (0.83) | ADRA1AHRH1ADRA1BKCNH2HRH3 | |
| SCHEMBL2428427 | 0.88 | ADRA1A (0.84) | ADRA1AHRH1ADRA1BKCNH2HRH3 | |
| SCHEMBL2994321 | 0.88 | HRH1 (0.78) | ADRA1AHRH1ADRA1BKCNH2HRH3 | |
| SCHEMBL2425882 | 0.87 | ADRA1A (0.82) | ADRA1AHRH1ADRA1BKCNH2HRH3 | |
| SCHEMBL13241560 | 0.86 | HRH1 (0.79) | ADRA1AHRH1ADRA1BKCNH2HRH3 | |
| SCHEMBL2436781 | 0.85 | ADRA1A (0.73) | ADRA1AHRH1ADRA1BKCNH2HRH3 | |
| SCHEMBL2999765 | 0.85 | HRH1 (0.78) | ADRA1AHRH1ADRA1BKCNH2HRH3 | |
| SCHEMBL13241575 | 0.84 | HRH1 (0.80) | ADRA1AHRH1ADRA1BKCNH2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100184770-A1 | COMPOUNDS | GLAXO GROUP LIMITED | 2010-07-22 | — | — | US | disclosed |
| US-20100184770-A1 | COMPOUNDS | GLAXO GROUP LIMITED | 2010-07-22 | — | — | US | disclosed |
| US-20100184770-A1 | COMPOUNDS | GLAXO GROUP LIMITED | 2010-07-22 | — | — | US | disclosed |
| EP-2091538-B1 | 4-BENZYL-1(2H)-PHTHALAZINONES AS H1 RECEPTOR ANTAGONISTS | GLAXO GROUP LTD (GB) | 2010-03-03 | — | — | EP | disclosed |
| EP-2091538-B1 | 4-BENZYL-1(2H)-PHTHALAZINONES AS H1 RECEPTOR ANTAGONISTS | GLAXO GROUP LTD (GB) | 2010-03-03 | — | — | EP | disclosed |
| WO-2008074803-A2 | 4-BENZYL-L ( 2H) -PHTHALAZINONES AS H1 RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184770-A1 | COMPOUNDS | CMA1, TSLP, IL5 | ADRA1A 592/4885HRH1 4/4885ADRA1B 464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.